When scientists Phillipe Horvath and Rodolphe Barrangou set out to find a better way to make yogurt, they didn't expect to stumble across one of the future's most promising discoveries: a super protein that can accurately cut DNAand could perhaps revolutionize genetic engineering.

The protein, called Cas9, can be exploited to snip strands of DNA in exactly the place researchers want. It doesn't make genetic engineering easy, but does make it much, much easieras it allows researchers to splice sequences of DNA together affordably, with unprecedented accuracy.

So how does it work? Well, Cas9 was found last year to join forces with bacteria in such a way that, combined, they home into viruses and kill them by cutting their DNA at specific, targeted points. That's interestingin fact, it made it a prime candidate for making yogurt production more efficient.

But what's more interesting is that Cas9 can be paired with any string of RNAstrings of molecules not unlike DNA which code and regulate gene expressionto target a matching piece of DNA and snip it with incredible accuracy. Kind of like a pair of tiny, custom DNA scissors. That's not interestingthat's amazing.

Now, though, reports Forbes, the world of biology is swarming over Cas9 and the possibilities it affords. George Church of Harvard University explains:

"It is spreading like wildfire from everyone who knows about it and it certainly is very tantalizing. It's easy to get in and start doing lots of experiments."

The embrace of Cas9 could bring with it massive advances, then. Not least the ability to study genetics in ways never before possible. Forbes explains:

[S]ay there are three changes in the DNA in or around a gene that might cause a disease. Right now, it's hard to study them directly. But now, Church says, you could take a cell from a person who has already had their DNA sequenced, as he is doing with his Personal Genome Project. Then you'd create what's known as an induced pluripotent stem cell, a cell that behaves much like one in an embryo. After that, you could use Cas9 to change each of those DNA spelling changes.

There is, of course, still a long way to gothis research is being conducted in Petri dishes right now, not living creaturesbut it's a long time since a single protein had the entire world of biology so excited. It's only a matter of time before something major comes of it; not bad, for a protein which was originally discovered to make better yogurt. [Forbes, Science]

See original here:
The Super Protein That Can Cut DNA and Revolutionize Genetic Engineering

Recommendation and review posted by Bethany Smith

America #39;s Newsroom with Erich Pratt on the Feinstein Assault Weapon Ban
January 25, 2013 - Fox News Channel "America #39;s Newsroom" host Bill Hemmer talks with Erich Pratt, Director of Communications at Gun Owners of America, about ...

By: GunOwnersofAmerica

Continued here:
America's Newsroom with Erich Pratt on the Feinstein Assault Weapon Ban - Video

Recommendation and review posted by Bethany Smith

Let Your Light Shine
Family Appreciation 2013.

By: Dorina Atkins

Visit link:
Let Your Light Shine - Video

Recommendation and review posted by Bethany Smith

PGM Second Lesson, Last Swings
PGM Second Lesson, Last Swings.

By: Mary Hashagen

View original post here:
PGM Second Lesson, Last Swings - Video

Recommendation and review posted by Bethany Smith

GIRLS VS MRE #39;S
OPEN ME!! So me and Makayla made this video a while ago...before the snow obviously. Her brother Matthew is a Marine and he sent the MRE #39;s to her. MRE=Meals ...

By: lizaajane

More here:
GIRLS VS MRE'S - Video

Recommendation and review posted by Bethany Smith

Released: 3/14/2013 4:00 PM EDT Embargo expired: 3/20/2013 5:00 PM EDT Source Newsroom: Mayo Clinic

Study to be presented at the annual meeting of the American Academy of Neurology by NorthShore University HealthSystem and Mayo Clinic

Newswise SAN DIEGO -- NorthShore University HealthSystem (NorthShore) and Mayo Clinic researchers have partnered on a study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinsons disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinsons disease.

Our research suggests therapies that seek to suppress alpha-synuclein in Parkinsons disease may actually accelerate the disease process and increase the risk for developing severe physical disability and dementia, says lead author Demetrius Maraganore, M.D., Ruth Cain Ruggles Chairman, Department of Neurology at NorthShore. We believe it is our responsibility to release these data because this type of treatment may have long-term harmful effects.

Alpha-synuclein is a major component of Lewy bodies -- a characteristic brain cell abnormality that occurs in all cases of Parkinsons disease. Since its discovery as a cause of familial Parkinsons disease nearly 20 years ago, alpha-synuclein has been the focus of intensive efforts by researchers working to definitively characterize the proteins role in idiopathic Parkinsons disease and its potential as a target for neuroprotective therapies. It has also been the focus of multiple efforts to develop a molecule that suppresses the protein function. A vaccine that targets alpha-synuclein (reducing alpha-synuclein levels) is currently in Phase I clinical trials, and a number of molecules that target the protein for reduction are in advanced stages of preclinical development.

For the first time we observed that while over-expression of alpha-synuclein increases the risk for developing Parkinsons disease, conversely, under-expression is associated with worse motor and cognitive outcomes after the disease starts, says first author Katerina Markopoulou, M.D., Ph.D., a neurologist at NorthShore. This raises concerns about the efficacy and safety of therapies designed to reduce alpha-synuclein expression in Parkinsons disease.

The researchers followed 1,098 Mayo Clinic patients for nearly 15 years (median: eight years), and sequenced the patients DNA to determine the presence of gene variants that regulate how much alpha-synuclein protein is made. They studied the association of these gene variants with patients survival that was free of severe motor and cognitive disabilities. Patient outcomes were measured by telephone interviews.

The scientists found that patients who had the reduced expression genotype had a 23 percent greater risk of becoming wheelchair-dependent or developing dementia.

This is the first large genetic association study of alpha-synuclein and longitudinal outcomes in Parkinsons disease, says Eric Ahlskog, M.D., Ph.D., a Mayo Clinic neurologist and author on the study. If replicated, this research may change the treatment paradigm focused on alpha-synuclein reduction for Parkinsons disease.

The study will be discussed at 5 p.m. EST, March 20 at the 2013 American Academy of Neurology (AAN) Annual Meeting in San Diego. This research is one example of the collaborative efforts between NorthShore and Mayo Clinic under the Mayo Clinic Care Network, a unique partnership that provides NorthShore patients with access to medical resources and experts from both systems working together on their behalf.

Go here to see the original:
Research Shows Genetic Evidence that New Therapies Targeting Parkinson's Disease may Cause Harm

Recommendation and review posted by Bethany Smith

The cold frozen north and south are pristine and innocent. Even the people who live there. People living in Arctic areas can be more sensitive to pollutants due to their genetics, says researcher Arja Rautio at the Center for Arctic Medicine in the University of Oulu, Finland. This is unfortunate since the northernmost areas of Europe are receiving more harmful chemicals. Scientists believe climate change may be a culprit as air and water mass movements push some of these undesirable chemicals towards the Arctic. "In real life, people are exposed to lots of chemicals," says Rautio, who leads studies into the human health effects from contaminants and the influence of climate change in a EU-funded project called ArcRisk, "and I think the people of the north are exposed to higher levels than for example the general population in Europe."

The Arctic is a polar region located at the northernmost part of the Earth. The Arctic consists of the Arctic Ocean and parts of Canada, Russia, Denmark (Greenland), Norway, the United States (Alaska), Sweden, Finland, and Iceland. The Arctic region consists of a vast, ice-covered ocean, surrounded by treeless permafrost.

Long-range transport of contaminants to the Arctic, the resulting exposures observed in Arctic human populations, and impacts of such exposures on human health have been the subject of considerable work in recent years, providing a baseline against which to compare future developments.

The Arctic is comparatively clean, although there are certain ecologically difficult localized pollution problems that present a serious threat to peoples health living around these pollution sources. Due to the prevailing worldwide sea and air currents, the Arctic area is the fallout region for long-range transport pollutants, and in some places the concentrations exceed the levels of densely populated urban areas. An example of this is the phenomenon of Arctic haze, which is commonly blamed on long-range pollutants. Another example is with the bioaccumulation of PCB's (polychlorinated biphenyls) in Arctic wildlife and people.

Many new contaminants like fluorinated and brominated compounds and bisphenol A can act on hormones and so have impacts on human health. But seeing an effect on humans, at the population level, could take ten or even 20 years, especially in the case of cancer, she adds. This is why ArcRisk has established a database containing data on concentration levels and trends of contaminants in humans. The project team analysed frozen blood samples collected in Norway in 1978, 1986, 1995 and 2008 for polychlorinated biphenyls (PCBs), chlorinated pesticides and polybrominated diphenylethers (PBDEs).

In addition, the human population is genetically variable and may react differently to the chemicals and we dont even know which of the chemicals affect us.

"Moreover, some of these chemicals reside in the environment and in the body for a long time, and this means that they may build up," says Zoeller. His recently edited a recent World Health Organization report which warned that chronic diseases are increasing worldwide and many are related to hormones.

Health problems induced by these chemicals could be worse than anticipated. Some of the pollutants found in the Arctic by the project scientists like the fluorinated compounds have higher affinities for hormone receptors than even the natural hormones.

These animal studies already show worrying trends that do not bode well for humans. "When we see these findings in Arctic animals I am very concerned about what we will find with regards to humans, though we ourselves dont do human studies," Gabrielsen says. He notes that long periods of warm air are being transported to the Arctic and that the sea currents around places like the Svalbard islands [located midway between Norway and the North Pole] now consist of warmer Atlantic water; they used to consist of polar waters. "Climate change is having an effect and it is resulting in higher levels of contaminants in the environment and [therefore] also in the animals," Gabrielsen warns.

The main challenge that project scientists struggle with is to disentangle the effects of contaminant chemicals from what we do in our everyday lives. "We know that dioxins can lead to more diabetes and high blood pressure," says Rautio, "but there are many other confounding factors. We are changing our diet and many of us are less active and those lifestyle choices can also increase the risk of diseases like diabetes." The results of the project are due to be presented at a conference of Arctic Frontiers in Troms, Norway, in January 2014.

View post:
Arctic Genetic Pollution Effects

Recommendation and review posted by Bethany Smith

DUBLIN, March 20, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Personalized Medicine: Companies, Trends and World Market" report to their offering.

This broad, high-level report analyzes the expanding Personalized Medicine market. This world market includes important core medical product areas that will continue to have a powerful impact on current and future healthcare delivery. This business report examines key market segments such as targeted drugs and key personalized medicine diagnostics, including companion diagnostic IVDs, LDTs, diagnostic services and related tools or technologies.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Many people already know about DNA, genes and the human genome. The science driving personalized medicine includes pharmacogenetics, pharmacoproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test). The companion diagnostic identifies which patients would likely benefit from a particular therapy or those who might suffer from a bad side effect. The test information enables doctors to select the drug therapy that would benefit the patient. Drug developers in clinical trials could use a companion diagnostic to select patents that would benefit from a targeted drug.

The report discusses important technologies, including microarray, next-generation sequencing, PCR, bioinformatics, nanotechnology and other platforms. This section highlights key platforms and selected vendors. For example, the field of clinical next generation sequencing is expected to have an impact on personalized medicine.

The report covers subjects including important personalized medicine concepts. The study discusses key biomarkers, commercial diagnostics and therapeutics that drive personalized medicine. The study highlights new personalized diagnostics. This research examines the current targeted therapeutics on the market and drugs in the clinical pipeline.

The report highlights major government regulatory activities that involve personalized medicine in the US and Europe. The US FDA and the European EMA have drafted guidance papers to help drug makers and diagnostic firms develop future targeted therapies guided by companion diagnostics. The recent FDA approvals of Pfizer's Xalkori for lung cancer and Roche's Zelboraf for melanoma demonstrate that a surge in new targeted drugs is happening.

This report is in an interactive PDF format. The interactive feature uses hyperlinks that enable the reader to click the mouse to jump from Table of Contents items to sections inside the report. The hyperlinks also allow the reader to click on links to Internet information.

This study discusses important personalized medicine topics and provides the reader with key findings. The report estimates that the world personalized medicine market value will reach multi-billions of dollars in 2012, with a strong double-digit growth rate. This study reviews the activities of 31 companies.

Originally posted here:
Personalized Medicine : Companies, Trends and World Market

Recommendation and review posted by Bethany Smith

AUSTIN, Texas, March 21, 2013 /PRNewswire/ -- Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter can improve the determination of a woman's risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of "interrupting" DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism

"The increased testing of women for fragile X status has led to the identification of carriers whose risk of having a child with fragile X syndrome is unknown," said Sally Nolin, Ph.D., Director of the Fragile X Laboratory at the New York Institute for Basic Research in Developmental Disabilities and lead author on the paper. "We are now able to better estimate this risk so that women who are fragile X intermediate or premutation carriers can be counseled with the best possible information."

Fragile X syndrome is caused by a mutation in the FMR1 gene that alters the production of a protein required for normal brain development. The mutation is the result of a small part of the genetic code (CGG) being repeated on a fragile area of the X chromosome. Repeat CGG sequences are categorized into four classes based on repeat length: normal (<45 repeats); intermediate (45-54 repeats); premutation (55-200 repeats); and full mutation (>200 repeats).

"A mother with more than 55 CGG repeats in her fragile X gene may be perfectly normal, yet instability of this gene can result in fragile X syndrome in her child," said Gary Latham, Ph.D., Vice President of Research and Technology Development at Asuragen. "Xpansion Interpreter predicts the risk of CGG expansion in the child by identifying the presence of another unique DNA sequence in the gene an AGG sequence that acts as a stabilizer in the string of CGG repeats and protects against expansion."

The published study, performed in collaboration with the New York Institute for Basic Research in Developmental Disabilities, Rush University Medical Center, Emory University School of Medicine and the M.I.N.D. Institute at the University of California Davis, evaluated AGG interruptions in 457 mother-to-child transmissions in women with intermediate or small premutation fragile X alleles (45-69 CGG repeats). The results revealed that the number and position of AGG interruptions, coupled with total number of CGG repeats, provide significant improvements over current risk estimates in predicting fragile X gene instability and expansion to a full fragile X mutation. All nine transmissions of the full fragile X expansion mutation in the study were from mothers with CGG repeat regions lacking AGG sequences.

"The difference in expansion risk for premutation carriers without any AGG is much higher than those with one or two AGGs," said Dr. Nolin. "Our study demonstrates that women with 50-54 repeats and no AGG interruptions may expand to larger, premutation alleles. In addition, there is a clear risk of fragile X syndrome in the children of women with small premutation alleles without AGG. These women should be offered the option of fragile X prenatal testing."

The Xpansion Interpreter Test is made available through Asuragen's accredited clinical laboratory in Austin, TX. Asuragen developed the methods and process to overcome formidable technological challenges and make FMR1 genotyping efficient and AGG sequence mapping accurate for use in clinical practice.

"AGG profiling complements our AmplideX fragile X PCR technologies that also offer unprecedented sensitivity in detecting fragile X mutations, and the ability to determine methylation status of each FMR1 allele without the need for Southern blot analysis," said Rollie Carlson, Ph.D., President & CEO of Asuragen. "Our experience and technological capability have made Asuragen an industry leading provider of solutions for fragile X profiling."

About AsuragenAsuragen is a molecular diagnostics company with a pioneering position in miRNA using genomics to drive better patient management through best-in-class clinical testing solutions. The company uses a breadth of technologies and talent to discover, develop and commercialize diagnostic products and clinical testing services with efficiency and flexibility both internally and for our companion diagnostic partners. Today, Asuragen's products, services and technologies drive countless patient management decisions across oncology, genetic disease and other molecular testing modalities. In the future, we envision the Company's development of miRNA-based clinical diagnostics will help transform medicine by improving clinical outcomes and health economics. For more information, visit http://www.asuragen.com.

Link:
Study Finds New Genetic Test Better Predicts Mother's Risk of Having a Child With Fragile X Syndrome

Recommendation and review posted by Bethany Smith

Public release date: 21-Mar-2013 [ | E-mail | Share ]

Contact: Tom Langford tlangford@partners.org 617-534-1605 Brigham and Women's Hospital

Boston In a highly anticipated report, landmark recommendations on the handling of incidental findings in clinical genome and exome sequencing are being issued from the American College of Medical Genetics and Genomics (ACMG). A report of the recommendations, led by Robert C. Green, MD, MPH, a medical geneticist at Brigham and Women's Hospital (BWH), outlines for the first time a minimum list of genetic conditions, genes and variants that laboratories performing clinical sequencing should seek and report to the physicians that ordered the testing -- regardless of the original reasons for which the test was ordered.

"If, as expected, these recommendations are adopted by laboratories and clinicians, they will have important implications," said Green, who also co-chaired the ACMG Working Group that developed the recommendations. "As clinical sequencing becomes more widespread, laboratories are looking for guidance on how and what should be communicated to clinicians when results are analyzed. These recommendations will allow a small percentage of families to learn unexpected but potentially life-saving information about an illness they may have never suspected they were at risk for."

The recommendations are the result of a year-long process which included review by outside experts and approval by the ACMG Board of Directors. Leslie Biesecker, MD, chief and senior investigator of the Genetic Diseases Research Branch at the National Human Genome Research Institute co-chaired the working group with Dr. Green.

"Incidental findings" are health-related interpretations of a patient's genetic code that are unrelated to the primary reason for ordering the genetic testing. For example, if a clinician orders exome or genome sequencing to analyze genes related to a patient's cardiac condition, the laboratory will already have information about all the other genes in hand and could examine genes for something like cancer predisposition with relative ease. Should a known or suspected mutation be found in a cancer predisposition gene, the laboratory would report this incidental findings back to the ordering clinician, and the clinician and patient could take steps to screen for cancer. However, in the absence of accepted guidelines about which variants to search for and which results to return to the clinician, laboratories have been uncertain whether to search for or report results beyond those that the doctor ordered.

"We are at an early stage in the implementation of genomic medicine, and this is a difficult topic to manage because there is not yet much scientific evidence to support whether returning incidental findings can provide medical benefit," said Dr. Green. "Based upon existing evidence and clinical judgment, our Working Group of medical geneticists, genetic counselors, ethicists and molecular laboratorians reached consensus that a small number of conditions, genes and variants were likely to have a positive impact on the health of patients and their families if incidentally identified and reported."

In assembling this list, the Working Group prioritized the disclosure of disorders where:

Examples of diseases recommended for disclosure include rare hereditary cancers and rare heart diseases that could result in sudden cardiac death. The full recommendations are available on the ACMG's website.

Because clinical sequencing is an entirely new technology, the recommendations include several provisions that deviate from established practices in medical genetics. For example, the Working Group did not recommend giving patients a choice of whether or not their physician would receive positive results from the list of recommended incidental findings. The Working Group also recommended that adult-onset conditions on the list be reported even when the patient is a minor. Dr. Green acknowledged that these recommendations diverge from current practices in medical genetics, explaining, "Sequencing offers a brand new way of looking at genetic testing. The Working Group believes that when we can detect findings that could provide clues to a dangerous condition for which a medical intervention may be possible, laboratories and clinicians have a responsibility to alert the patient's physician, as is done in the rest of medical practice."

The rest is here:
For the first time, recommendations offer guidance about incidental genetic findings

Recommendation and review posted by Bethany Smith

SAN DIEGO, March 21, 2013 /PRNewswire/ --Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Sequenom Center for Molecular Medicine (SCMM) has launched an advanced new cystic fibrosis carrier screen test branded under the name Heredi-T. The laboratory-developed test (LDT) is now available as a testing service to ordering physicians.

The Heredi-T Cystic Fibrosis (CF) test analyzes 136 mutations and five variants proven to be clinically relevant in causing CF, integrating disease causing mutations selected from the Johns Hopkins CFTR2 database (http://www.cftr2.org). The LDT analyzes nearly six times the number of mutations currently available in other screening methods and can be performed preconception or at any time during pregnancy with a DNA sample obtained from a buccal swab.

"The Heredi-T test provides significant new clinical value, offering highly reliable information about a patient's risk of being a cystic fibrosis carrier," said Bill Welch, President and COO of Sequenom. "This introduction adds to Sequenom CMM's leadership in prenatal testing and supports our mission to help health care providers and their patients make more informed clinical decisions through the use of advanced genetics."

The American College of Obstetricians and Gynecologists (ACOG) recommends cystic fibrosis carrier screening for all patients. According to ACOG, additional screening consideration should be given to patients with the following, as these clinical indicators increase the risk of CF:

Results of the Heredi-T CF test are delivered to the physician on average within seven business days. A positive Heredi-T CF test result indicates that the patient has one copy of a genetic mutation that is known to cause CF, and they should be advised to consider genetic counseling or further testing. A negative Heredi-T CF test result indicates a low risk for CF, but does not completely eliminate the risk because the test does not screen for all possible CF mutations.

About Cystic FibrosisCystic fibrosis (CF) is one of the most common genetic diseases in the United States. It is caused by changes in the CFTR gene. Changes in this gene cause the body to produce thick sticky mucus in the lungs, pancreas and other organs that can affect breathing and digestion. Symptoms can range from moderate to severe and can even impact fertility. It is estimated that more than 10 million Americans are carriers of CF. While the risk of being a CF carrier is dependent upon one's ethnicity and family history, individuals of all racial and ethnic groups may be carriers of CF.

About SequenomSequenom, Inc. (SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Sequenom Center for Molecular MedicineSequenom Center for Molecular Medicine (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the names MaterniT21 PLUS, Heredi-T, SensiGene and RetnaGene, these molecular genetic laboratory tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists, retina specialists and ophthalmologists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies. Visit http://www.sequenomcmm.comfor more information on laboratory testing services.

SEQUENOM, SEQUENOM CMM , MaterniT21 PLUS, Heredi-T, SensiGene and RetnaGene are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the expected benefits, impact, and value of the Heredi-T CF test to healthcare providers and their patients, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM's impact on the landscape in genetic diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the Heredi-T CF test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

The rest is here:
Sequenom, Inc. Announces The Availability Of Heredi-T™ Cystic Fibrosis Carrier Screening LDT Through Sequenom CMM

Recommendation and review posted by Bethany Smith

Heart Panel For Preventing Heart Disease | Larry King Now | Ora TV
Larry King experts discuss heart disease. Expert panel includes cardiologist Dr. Prediman K. (P.K.) Shah, cardiologist Dr. Liza Matzer, "The Biggest Loser"...

By: Ora TV

Read the rest here:
Heart Panel For Preventing Heart Disease | Larry King Now | Ora TV - Video

Recommendation and review posted by Bethany Smith

Heart Panel: Women Heart Disease | Larry King Now | Ora TV
Larry King experts discuss heart disease women. Expert panel includes cardiologist Dr. Prediman K. (P.K.) Shah, cardiologist Dr. Liza Matzer, "The Bigges...

By: Ora TV

Excerpt from:
Heart Panel: Women

Recommendation and review posted by Bethany Smith

As European as we can get - Do Europeans feel European ?
EESC Civil Society Day 2013.

By: EurEcoSocCommittee

See more here:
As European as we can get - Do Europeans feel European ? - Video

Recommendation and review posted by Bethany Smith

The Genetics of Obesity and Weight Loss
Obesity has become a worldwide epidemic. Although diet, exercise, and other aspects of modern living play important roles, there is strong evidence indicatin...

By: PennStateScience

Original post:
The Genetics of Obesity and Weight Loss - Video

Recommendation and review posted by Bethany Smith

5 Steps to Overhaul Teaching
Dr. Christopher Emdin is on a mission to revolutionize science instruction in America mdash;an area of education lacking in innovation since the post-Sputnik era. ...

By: thnkrtv

Originally posted here:
5 Steps to Overhaul Teaching - Video

Recommendation and review posted by Bethany Smith

DNA Genetics LA Woman
DNA Genetics LA Woman is LA Confidential crossed with Martian Mean Green. Debut of this marijuana strain in my grow room. See more on my website http://www.m...

By: Matt Mernagh

View post:
DNA Genetics LA Woman - Video

Recommendation and review posted by Bethany Smith

Codebreakers: Makers of Modern Genetics
Codebreakers: makers of modern genetics, brings together over a million pages of first-hand notes, letters, sketches, lectures, photographs and essays from t...

By: WellcomeCollection

Link:
Codebreakers: Makers of Modern Genetics - Video

Recommendation and review posted by Bethany Smith

Pirjo Mäkelä moving from genetics to modeling
Aino Takala, Orion. The role of infectious diseases research in advancing global health. Pirjo Mäkelä memorial symposium in Helsinki 10.12.2012.

By: Terveyden ja hyvinvoinnin Laitos

Read the rest here:
Pirjo Mäkelä moving from genetics to modeling - Video

Recommendation and review posted by Bethany Smith

Harvard Genetics Harlem shake!
Copyright Baauer - Harlem Shake.

By: tns278

More here:
Harvard Genetics Harlem shake! - Video

Recommendation and review posted by Bethany Smith

Genetics and comparisons
Quick chat about genetics and motivation!

By: Brittany Davila

Read more:
Genetics and comparisons - Video

Recommendation and review posted by Bethany Smith

The Online Revolution: Education for Everyone
In 2011, Stanford University offered three online courses, which anyone in the world could enroll in and take for free. Together, these three courses had enr...

By: UTexasCTL

View original post here:
The Online Revolution: Education for Everyone - Video

Recommendation and review posted by Bethany Smith

They STILL Can #39;t Grasp Heritability
Because their overarching ideological agenda is to deny any genetic contribution to extant racial variations in cognitive traits. Hannibal "Pieface" the Vanq...

By: LibertarianRealist2

Original post:
They STILL Can't Grasp Heritability - Video

Recommendation and review posted by Bethany Smith

Genetic Potential TV episode 1
Genetic Potential - the defining source of an athlete #39;s talent and performance. Join hosts Kelly Starrett and Brian MacKenzie as they ask and answer the esse...

By: GeneticPotentialTV

See more here:
Genetic Potential TV episode 1 - Video

Recommendation and review posted by Bethany Smith

Public release date: 20-Mar-2013 [ | E-mail | Share ]

Contact: Steve Yozwiak syozwiak@tgen.org 602-343-8704 The Translational Genomics Research Institute

PHOENIX, Ariz. March 20, 2013 Dr. Lisa Baumbach-Reardon, an Associate Professor at the Translational Genomics Research Institute (TGen), will lead a panel discussion about Arthrogryposis (ARGY) today at the 2013 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting.

Arthrogryposis is a complex congenital disorder associated with stunted muscular development. It is characterized by multiple contractures, stiff joints and limited movement in multiple parts of the body, usually in the arms and legs. It occurs in nearly 1 in every 3,000 births, and children are often born with the condition with no pre-birth indications.

"This is an area of medical study ripe for new genomic investigations," said Dr. Baumbach-Reardon, who is one of the co-monitors of the conference session, Advances in Classification: Genetic Diagnosis and Understanding of Arthrogryposis and Related Fetal Movement Disorders.

The session, scheduled for 10 a.m. Wednesday, March 20, at the Phoenix Convention Center, will focus on recent advances in clinical classification, genetic causes and the underlying biology of ARGY.

"Arthrogryposis is not a diagnosis, but a sign," said Dr. Judith Hall of the University of British Columbia Medical School, the other co-monitor of the panel and a former President of the American Society of Human Genetics. Treatment of Arthrogryposis should begin as soon as 6-8 weeks after conception, said Dr. Hall, yet nearly 75 percent of children with the condition remain undiagnosed prior to birth.

Other panel speakers are: Dr. Anna Sarkozy of Newcastle University in the United Kingdom, and Mar Tulinius of Sahlgrenska University Hospital in Sweden.

Dr. Baumbach-Reardon is an American Board of Medical Genetics (ABMG) certified scientist in Clinical Molecular and Biochemical Genetics. Her main research areas are the molecular basis of a number of inherited neurological and neuromuscular diseases, and the genetic basis of African-American breast cancer.

In October 2011, Dr. Baumbach-Reardon joined TGen's Integrated Cancer Genomics Division. She conducts groundbreaking work in the genomics of infantile motor-neuron diseases and of breast cancer, and is developing TGen's Dorrance Clinical Laboratory, the institute's new federally certified CLIA (Clinical Laboratory Improvement Act) DNA lab.

More:
TGen researcher leads distinguished international panel at genetics conference in Phoenix

Recommendation and review posted by Bethany Smith